Ticlopidine and platelet function in healthy volunteers.
The influence of a 4-weeks therapy with 500 mg ticlopidine daily on platelet function parameters was examined in 10 male healthy volunteers aged 20-33 years in order to extend the knowledge on the antiplatelet activity of this substance. Ticlopidine significantly (p less than 0.01) affected ex-vivo platelet aggregation induced by ADP and increased platelet sensitivity to the antiaggregatory action of PGI2. Generation of TXB2 from endogenous substrate during spontaneous clotting of blood (serum-TXB2), conversion of exogenous radiolabelled arachidonic acid into TXB2 and MDA-formation in isolated platelets were unaffected by the treatment. The TXB2-level in plasma of volunteers, however, was decreased, after administration of the drug. The diminished alpha-granule content liberation (beta-thromboglobulin: p less than 0.01; PDGF: p less than 0.01; PF4 not significant) indicates that ticlopidine induces a decrease in platelet activity. The beneficial effect on release reaction is not associated with a decrease in TXA2-formation. Our results demonstrate that ticlopidine inhibits platelet activity, especially the PDGF-release. These results confirm the value of this drug in the prevention of atherosclerosis and its thromboembolic complications.
Dembinska-Kiec
A
A
Department of Pharmacology, N. Copernicus Medical Academy, Cracow, Poland.
Virgolini
I
I
Rauscha
F
F
Sinzinger
H
H
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010979:Platelet Function Tests; D010982:Platelet-Derived Growth Factor / Q000187:drug effects / Q000378:metabolism*; D013929:Thromboxane B2; D013988:Ticlopidine / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D010982:Platelet-Derived Growth Factor; D013929:Thromboxane B2; D013988:Ticlopidine